BiVictriX gets patent for its lead asset in Japan
15th Nov 2023 12:55
(Sharecast News) - BiVictriX Therapeutics has received a patent grant from the Japanese Patent Office (JPO) for its lead asset BVX001, it announced on Wednesday.
Read moreBiVictriX posts promising preclinical data on leukaemia candidate
12th Oct 2023 13:44
(Sharecast News) - Biotechnology company BiVictriX Therapeutics updated the market on the pre-clinical evaluation of BVX001 on Thursday - its first-in-class 'Bi-Cygni' antibody drug conjugate (ADC) developed for the potential treatment of acute myeloid leukaemia (AML).
Read moreBiVictriX appoints Adrian Howd as its new finance chief
3rd Oct 2023 10:14
(Sharecast News) - Biotechnology developer BiVictriX Therapeutics announced the appointment of Dr Adrian Howd as its chief financial officer (CFO) and chief business officer (CBO) on Tuesday.
Read moreBiVictriX secures US patent for flagship therapeutic asset
23rd Aug 2023 14:29
(Sharecast News) - Cancer treatment developer BiVictriX Therapeutics has secured a significant patent from the United States Patent and Trademark Office (USPTO), it announced on Wednesday, for its flagship therapeutic asset, BVX001.
Read moreMichael Kauffman promoted to BiVictriX board chair
6th Jan 2023 15:03
(Sharecast News) - Cancer therapy developer BiVictriX Therapeutics announced on Friday that Dr Michael Kauffman has been appointed as its non-executive chairman.
Read moreBiVictriX identifies development lead for potential cancer drug
7th Dec 2022 16:35
(Sharecast News) - Cancer therapy-focussed biotechnology company BiVictriX Therapeutics has identified a development lead for its 'BVX001' programme, it announced on Wednesday.
Read moreBiVictriX upbeat on recent pipeline progress
11th Jul 2022 14:15
(Sharecast News) - Biotechnology company BiVictriX Therapeutics updated the market on its pipeline on Monday, reporting "significant progress" with its lead candidate, 'BVX001'.
Read moreBiVictriX adds two new drug development programmes
23rd Feb 2022 15:39
(Sharecast News) - Biotechnology company BiVictriX Therapeutics announced the expansion of its therapeutic pipeline on Wednesday, with two additional programmes - 'BVX002' and 'BVX003' - both entering the early stages of drug development.
Read moreBiVictriX files four new cancer therapy patents in UK
21st Feb 2022 13:16
(Sharecast News) - Cancer therapy-focussed biotechnology company BiVictriX Therapeutics has filed four new patent applications in the UK, it announced on Monday, related to several novel cancer-specific antigen pairs - or 'fingerprints' - across a range of oncology indications.
Read moreBiVictriX taps Glyn Baker as its new finance chief
6th Jan 2022 15:25
(Sharecast News) - Cancer therapy biotechnology company BiVictriX Therapeutics announced the appointment of Glyn Baker as its chief financial officer on Thursday, in a non-board role.
Read more